Published in Lancet on February 21, 1998
Antiretroviral Therapy for Advanced HIV Disease in South Africa | NCT00342355
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A (2011) 4.68
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 3.35
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med (2011) 2.99
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med (2000) 2.45
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 1.90
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci (2011) 1.73
Use of antiretroviral therapies among HIV-infected men who have sex with men: a household-based sample of 4 major American cities. Am J Public Health (2001) 1.63
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A (2001) 1.41
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health (1999) 1.22
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol (2000) 1.21
Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clin Exp Immunol (2000) 1.20
Accelerated publication versus usual publication in 2 leading medical journals. CMAJ (2002) 1.20
A review of the toxicity of HIV medications. J Med Toxicol (2014) 1.19
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses (2008) 1.15
Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14
Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am J Epidemiol (2009) 1.09
Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep (2007) 1.05
Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr (2008) 1.04
Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol (2007) 1.01
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (2003) 1.00
Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. Am J Epidemiol (2009) 0.98
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol (2005) 0.97
Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96
Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr (2010) 0.96
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother (2000) 0.96
A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. Stat Med (2012) 0.92
HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab (2008) 0.91
Surrogacy in HIV-1 clinical trials. Lancet (1998) 0.90
Profile of candidiasis in HIV infected patients. Iran J Microbiol (2012) 0.90
Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis (2006) 0.87
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother (2001) 0.87
Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005. AIDS Res Ther (2007) 0.85
Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. Antiviral Res (2013) 0.85
HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J (2003) 0.84
The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. Int J Epidemiol (2016) 0.84
Clinically informative measures of the effect of drugs or other interventions. Br J Clin Pharmacol (2008) 0.83
Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence (2012) 0.83
Identification and recovery of minor HIV-1 variants using the heteroduplex tracking assay and biotinylated probes. Nucleic Acids Res (2008) 0.83
Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. PLoS One (2013) 0.83
Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Eur J Epidemiol (2000) 0.83
Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina. Medscape J Med (2008) 0.83
Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina. J Int AIDS Soc (2008) 0.82
Palliative care for HIV disease in the era of highly active antiretroviral therapy. J Urban Health (2000) 0.81
Do coping styles mediate the relationship between substance use and educational attainment and antiretroviral adherence? AIDS Behav (2012) 0.81
Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health (2000) 0.81
Recent clinical history and cognitive dysfunction for attention and executive function among human immunodeficiency virus-infected patients. Arch Clin Neuropsychol (2011) 0.80
Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression. PLoS One (2014) 0.80
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother (2012) 0.78
Characteristics of HIV infection/AIDS in Korea. Korean J Intern Med (2001) 0.78
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. J Int AIDS Soc (2006) 0.78
Oral innate immunity in HIV infection in HAART era. J Oral Pathol Med (2015) 0.77
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 0.77
Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. CMAJ (2003) 0.77
The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol (2000) 0.76
Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines (2005) 0.76
Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates. Stat Med (2014) 0.76
Disease management--constructing optimal NRTI-based combinations: past, present, and future. MedGenMed (2006) 0.75
Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clin Exp Immunol (2002) 0.75
Response to a protease-inhibitor (ritonavir)-containing combination antiretroviral regimen in HIV-infected children. Can J Infect Dis (2003) 0.75
Pathogenesis and treatment of human immunodeficiency virus lipodystrophy. Indian J Endocrinol Metab (2012) 0.75
Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent. Front Public Health (2015) 0.75
Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions. J Virol (2016) 0.75
Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol (2000) 0.75
[Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders]. Wien Med Wochenschr (2006) 0.75
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Coverage by the news media of the benefits and risks of medications. N Engl J Med (2000) 7.50
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface. Proc Natl Acad Sci U S A (1981) 5.56
Use of hospital services by homeless families in an inner London health district. BMJ (1989) 4.71
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development (1995) 4.38
Promoting cost effective prescribing. BMJ (1995) 3.46
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Intern Med J (2005) 3.08
Three conformational states of scallop myosin S1. Proc Natl Acad Sci U S A (2000) 3.06
Comparing treatments. BMJ (1995) 3.02
Atomic structure of scallop myosin subfragment S1 complexed with MgADP: a novel conformation of the myosin head. Cell (1999) 2.99
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med (2001) 2.94
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Structure of the regulatory domain of scallop myosin at 2.8 A resolution. Nature (1994) 2.78
Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med (1983) 2.72
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med (2000) 2.68
Clinical application of pharmacogenetics. Trends Mol Med (2001) 2.67
A tropomyosin-like protein from human platelets. J Mol Biol (1972) 2.65
Tropomyosin crystal structure and muscle regulation. J Mol Biol (1986) 2.65
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ (1995) 2.61
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
The effects of information framing on the practices of physicians. J Gen Intern Med (1999) 2.52
Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill (2009) 2.47
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Structure of the regulatory domain of scallop myosin at 2 A resolution: implications for regulation. Structure (1996) 2.45
Paramyosin and the filaments of molluscan "catch" muscles. II. Native filaments: isolation and characterization. J Mol Biol (1971) 2.42
Heptad breaks in alpha-helical coiled coils: stutters and stammers. Proteins (1996) 2.30
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol (1991) 2.27
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Disease mongering: expanding the boundaries of treatable disease. Intern Med J (2008) 2.19
Crystal structure and molecular interactions of tropomyosin. Nature (1979) 2.16
Deciphering the design of the tropomyosin molecule. Proc Natl Acad Sci U S A (2001) 2.14
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ (1999) 2.11
Laparoscopic live donor nephrectomy: the recipient. Transplantation (2000) 2.11
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM (2005) 1.97
The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol (1993) 1.96
Leishmaniasis acquired in Belgium. Lancet (1991) 1.93
The surgical management of nontraumatic ectopic lenses. J Pediatr Ophthalmol Strabismus (1996) 1.91
Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol (1990) 1.91
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol (2001) 1.89
Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol Endocrinol (1994) 1.89
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis (1999) 1.87
Comprehensive management of children on a paediatric ward: a family approach. Arch Dis Child (1980) 1.86
Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med (2004) 1.84
X-ray diffraction from microtubules. J Mol Biol (1971) 1.84
Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A (1993) 1.82
Crystallographic findings on the internally uncoupled and near-rigor states of myosin: further insights into the mechanics of the motor. Proc Natl Acad Sci U S A (2002) 1.81
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res (1990) 1.80
Tropomyosin: crystal structure, polymorphism and molecular interactions. J Mol Biol (1969) 1.79
A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci U S A (1975) 1.76
Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ (1993) 1.76
Ethics and evidence based medicine. BMJ (1998) 1.74
Tropomyosin paracrystals formed by divalent cations. Science (1966) 1.73
The Test for Severe Impairment: an instrument for the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc (1992) 1.72
Incidence and natural history of phrenic neuropathy occurring during open heart surgery. Chest (1993) 1.68
The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci U S A (2000) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Electron microscopy of thin filaments decorated with a Ca2+-regulated myosin. J Mol Biol (1980) 1.64
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther (2000) 1.62
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis (1999) 1.61
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 1.60
Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J Acquir Immune Defic Syndr (1999) 1.59
Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat (2008) 1.58
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 1.58
Association of an HLA-DQ allele with clinical tuberculosis. JAMA (1998) 1.58
Transcriptional regulation of the human insulin gene is dependent on the homeodomain protein STF1/IPF1 acting through the CT boxes. Proc Natl Acad Sci U S A (1994) 1.56
Microtubule structure at 18 A resolution. J Mol Biol (1987) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Social and community resources and long-term recovery from treated and untreated alcoholism. J Stud Alcohol (1997) 1.55
Activation of the human immunodeficiency virus by herpes simplex virus type 1. J Virol (1987) 1.55
Design of a safer approach to intravenous drug infusions: failure mode effects analysis. Qual Saf Health Care (2004) 1.55
Catecholamines in fetal and newborn rat brain. J Neurochem (1973) 1.55
A model for fibrinogen: domains and sequence. Science (1985) 1.53
A 29 residue region of the sarcomeric myosin rod is necessary for filament formation. J Mol Biol (1997) 1.52
A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest (1998) 1.51
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Clin Infect Dis (1995) 1.51
Clinical comparison of isolator and BACTEC 660 resin media for blood culture. J Clin Microbiol (1990) 1.51
Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet (1979) 1.50
Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet (1992) 1.49
Cross-bridge arrangements in Limulus muscle. J Mol Biol (1974) 1.48
Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. J Neuropathol Exp Neurol (1999) 1.48
A model of Ca(2+)-free calmodulin binding to unconventional myosins reveals how calmodulin acts as a regulatory switch. Structure (1996) 1.48
Troponin and its interactions with tropomyosin. An electron microscope study. J Mol Biol (1982) 1.48
Paramyosin and the filaments of molluscan "catch" muscles. I. Paramyosin: structure and assembly. J Mol Biol (1971) 1.47